TYRA Stock Forecast: Tyra Biosciences, Inc. Price Predictions for 2026-2027
The 15 Wall Street analysts covering Tyra Biosciences, Inc. hold a median 12-month price target of $50 — +148.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 28 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Tyra Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (82): The share price has been relatively steady.
Growth (22): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
TYRA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TYRA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +148.6% from it.
Of the 20 most recent actions, 3 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Nov 2026 | Guggenheim | Assumes | Buy | $54 → $55 |
| 11 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $29 → $27 |
| 11 Nov 2026 | Wedbush | Maintains | Outperform | $53 → $57 |
| 22 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $30 → $29 |
| 22 Sept 2026 | Oppenheimer | Reiterates | Outperform | $50 → $40 |
| 10 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $45 → $30 |
| 10 Sept 2026 | Wedbush | Reiterates | Outperform | $53 |
| 4 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $45 |
| 17 June 2026 | Jones Trading | Initiates | Buy | $56 |
| 10 June 2026 | B of A Securities | Maintains | Buy | $37 → $42 |
| 19 May 2026 | Wolfe Research | Initiates | Peer Perform | — |
| 14 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Apr 2026 | Guggenheim | Initiates | Buy | — |
| 6 Apr 2026 | Canaccord Genuity | Initiates | Buy | — |
| 20 Mar 2026 | Piper Sandler | Maintains | Overweight | — |
| 24 Feb 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 17 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Feb 2026 | Wedbush | Maintains | Outperform | — |
| 3 Feb 2026 | Jefferies | Maintains | Buy | — |
| 3 Feb 2026 | Oppenheimer | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TYRA.
This page is one stock. Monday covers all of them.
TYRA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
TYRA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Tyra Biosciences, Inc. returned −4.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
TYRA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 2.0×
- EV / EBITDA
- —
Cheaper than 43% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −34.9%
- Return on assets
- −22.1%
- Dividend yield
- —
Higher than 26% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Tyra Biosciences, Inc. has a market value of $1.4B and an enterprise value of $694.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$148.6M.
Diluted earnings per share, trailing twelve months: −$2.40.
Free cash flow in the twelve months to 30 June 2026: −$109.9M.
Tyra Biosciences, Inc. employs 87 people.
Data provided by Twelve Data
TYRA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at TYRA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Tyra Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about TYRA
What is the TYRA stock price forecast for 2026-2027?
The 15 Wall Street analysts covering Tyra Biosciences, Inc. have a median 12-month price target of $50, with estimates ranging from $27 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is TYRA stock a buy right now?
Of the 15 analysts covering Tyra Biosciences, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tyra Biosciences, Inc. 28 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TYRA?
As at 21 Nov 2026, Tyra Biosciences, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (82 of 100).
Will TYRA stock go up?
No one can know that. What the data says: the median 12-month target from 15 analysts implies +148.6% from the last close, and Ticker Nerd's factor model ranks Tyra Biosciences, Inc. 28 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the TYRA stock forecast for 2030?
No analyst covering Tyra Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TYRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $59 over the next 12 months.
How has TYRA stock performed over the past year?
Tyra Biosciences, Inc. returned -4.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Tyra Biosciences, Inc. do?
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target fibroblast growth factor receptor (FGFR) biology. The company’s core work centers on designing small-molecule therapies for genetically defined cancers and rare skeletal disorders, using its SNÅP platform to support structure-guided drug discovery and rapid optimization.
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target fibroblast growth factor receptor (FGFR) biology. The company’s core work centers on designing small-molecule therapies for genetically defined cancers and rare skeletal disorders, using its SNÅP platform to support structure-guided drug discovery and rapid optimization. Tyra Biosciences is advancing oral dabogratinib across urologic cancers and skeletal dysplasia programs, alongside other FGFR-targeted candidates in its pipeline. Its current business is built around clinical development, translational research, and precision oncology, with an emphasis on conditions where specific genetic alterations drive disease. Headquartered in Carlsbad, California, Tyra Biosciences operates as a focused biotechnology developer serving the oncology and rare disease markets.
CEO Dr. Todd Harris Ph.D. · 87 employees · United States · https://tyra.bio